Clinical applications and pharmacological characteristics of remimazolam, a short-acting sedative: a narrative review
- Author:
Kyung Mi KIM
1
Author Information
- Publication Type:Focused issue of this month
- From:Journal of the Korean Medical Association 2026;69(4):335-343
- CountryRepublic of Korea
- Language:Korean
- Abstract: Remimazolam is a novel, ultra–short-acting benzodiazepine. Developed as a “soft drug,” it is rapidly metabolized by tissue esterases into an inactive metabolite. This metabolism enables fast onset, predictable offset, and straightforward reversibility with flumazenil, distinguishing it from non-benzodiazepine hypnotics.Current concepts: Pharmacokinetically, remimazolam exhibits high clearance, a small steady-state volume of distribution, and a short context-sensitive half-time, which help minimize accumulation during prolonged infusions. Pharmacodynamically, it produces dose-dependent sedation by modulating the GABAA receptor and demonstrates consistent concentration–response relationships. Clinically, randomized and observational studies support its efficacy in procedural sedation and general anesthesia. Remimazolam is associated with stable hemodynamics, reduced vasopressor requirements, and minimal respiratory compromise. Older adults and high-risk patients often experience favorable recovery profiles, and remimazolam shows promise in neurosurgery, where rapid neurological assessment is essential.Discussion and conclusion: Several challenges remain, presenting opportunities for innovation. Sporadic cases of reported anaphylaxis may involve remimazolam itself or the dextran-40 excipient, necessitate careful administration and warrant research into optimized infusion strategies. Reports of resedation after flumazenil antagonism underscore the need for extended recovery monitoring and highlight areas for clinical refinement. Limited pediatric data emphasize the importance of establishing standardized dosing regimens. Discrepancies between bispectral index values and actual hypnotic depth indicate the need to identify drug-specific electroencephalography (EEG) markers. Overall, remimazolam represents a promising alternative to conventional sedative-hypnotics, especially when hemodynamic stability and rapid, reversible hypnosis are priorities. Future studies should prioritize refining dosing strategies for special populations, validating EEG markers, and evaluating long-term cognitive outcomes and cost-effectiveness.
